Cargando…
Safety of an Abbreviated Transition Period When Switching From Intravenous Immunoglobulin to Eculizumab in Patients with Treatment-Refractory Myasthenia Gravis: A Case Series
Case series Patient: — Final Diagnosis: Generalized myasthenia gravis Symptoms: Muscle weakness Medication: IVIg • eculizumab Clinical Procedure: Transition from IVIg to eculizumab Specialty: Neurology OBJECTIVE: Unusual setting of medical care BACKGROUND: Eculizumab is a terminal complement inhibit...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
International Scientific Literature, Inc.
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6628751/ https://www.ncbi.nlm.nih.gov/pubmed/31278249 http://dx.doi.org/10.12659/AJCR.916424 |